Oppenheimer Asset Management Inc. lifted its holdings in shares of Inogen Inc (NASDAQ:INGN) by 2,688.5% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 3,402 shares of the medical technology company’s stock after acquiring an additional 3,280 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Inogen were worth $227,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. BBT Capital Management LLC acquired a new stake in shares of Inogen during the second quarter worth about $442,000. Rockefeller Capital Management L.P. lifted its holdings in shares of Inogen by 27.6% during the second quarter. Rockefeller Capital Management L.P. now owns 221,144 shares of the medical technology company’s stock worth $14,764,000 after purchasing an additional 47,849 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Inogen by 42.8% during the second quarter. Russell Investments Group Ltd. now owns 48,186 shares of the medical technology company’s stock worth $3,216,000 after purchasing an additional 14,450 shares during the period. Prudential Financial Inc. lifted its holdings in shares of Inogen by 5.9% during the second quarter. Prudential Financial Inc. now owns 12,157 shares of the medical technology company’s stock worth $812,000 after purchasing an additional 680 shares during the period. Finally, Asymmetry Capital Management L.P. lifted its holdings in shares of Inogen by 258.3% during the second quarter. Asymmetry Capital Management L.P. now owns 191,970 shares of the medical technology company’s stock worth $12,816,000 after purchasing an additional 138,395 shares during the period.

In related news, Director Loren L. Mcfarland purchased 1,000 shares of the firm’s stock in a transaction on Wednesday, September 4th. The stock was bought at an average cost of $42.93 per share, with a total value of $42,930.00. Following the completion of the acquisition, the director now owns 4,481 shares of the company’s stock, valued at approximately $192,369.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Heath Lukatch purchased 2,000 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was bought at an average cost of $43.01 per share, with a total value of $86,020.00. Following the completion of the acquisition, the director now directly owns 5,481 shares of the company’s stock, valued at approximately $235,737.81. The disclosure for this purchase can be found here. Insiders own 4.54% of the company’s stock.

INGN has been the subject of a number of research reports. Needham & Company LLC downgraded Inogen from a “buy” rating to a “hold” rating in a report on Wednesday, August 7th. Piper Jaffray Companies decreased their target price on Inogen from $140.00 to $80.00 and set an “overweight” rating for the company in a report on Wednesday, August 7th. JPMorgan Chase & Co. downgraded Inogen from a “neutral” rating to an “underweight” rating and set a $72.00 target price for the company. in a report on Wednesday, July 3rd. Svb Leerink reaffirmed a “market perform” rating and set a $47.00 target price (down previously from $78.00) on shares of Inogen in a report on Thursday, August 8th. Finally, KeyCorp reaffirmed a “hold” rating on shares of Inogen in a report on Wednesday, August 7th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $82.17.

NASDAQ:INGN traded up $2.82 during trading hours on Friday, reaching $49.90. The company had a trading volume of 52,915 shares, compared to its average volume of 455,786. Inogen Inc has a 1-year low of $41.19 and a 1-year high of $287.79. The firm has a market cap of $1.02 billion, a PE ratio of 21.64, a price-to-earnings-growth ratio of 2.76 and a beta of 1.50. The business’s 50 day moving average price is $48.80 and its 200-day moving average price is $72.28. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.35 and a quick ratio of 6.82.

Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Wednesday, August 7th. The medical technology company reported $0.45 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.50 by ($0.05). Inogen had a net margin of 11.24% and a return on equity of 13.34%. The company had revenue of $101.10 million during the quarter, compared to analyst estimates of $106.88 million. During the same period in the previous year, the firm posted $0.65 earnings per share. The company’s revenue was up 3.9% compared to the same quarter last year. On average, analysts expect that Inogen Inc will post 1.09 earnings per share for the current fiscal year.

About Inogen

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Read More: Book Value Of Equity Per Share – BVPS Explained

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen Inc (NASDAQ:INGN).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.